Gulilat, Markus
Lamb, Tyler
Teft, Wendy A.
Wang, Jian
Dron, Jacqueline S.
Robinson, John F.
Tirona, Rommel G.
Hegele, Robert A.
Kim, Richard B.
Schwarz, Ute I. http://orcid.org/0000-0003-1569-1580
Funding for this research was provided by:
Wolfe Medical Research Chair in Pharmacogenomics (n/a)
Canadian Institutes of Health Research (DSEN-PREVENT, FRN-117588)
Children’s Health Foundation, London, Canada (n/a)
Article History
Received: 7 January 2019
Accepted: 13 May 2019
First Online: 3 June 2019
Ethics approval and consent to participate
: Adult and pediatric studies have been approved by the Research Ethics Board of Western University, London, Canada (REB15586; REB107097). All subjects provided written informed consent except minor participants (those under the age of 12), where parents provided written informed consent. Children aged 13 to 17 years provided written informed consent, where the child and/or parents/ guardians were able to refuse to participate.
: Not applicable.
: R.B.K., R.G.T., and U.I.S. declare a pending US provisional patent application for PGxSeq.All other authors have no conflict of interest to disclose (M.G., T.L., W.A.T., J.W., J.S.D., J.F.R., R.A.H.).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.